B. Goldstein

Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding

A. Go, K. Reynolds, Nigel Gupta, 2022, Journal of Thrombosis and Thrombolysis.

Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents.

S. Seremetis, B. Geldziler, J. Bjerre, 2008, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

Surgical Experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX

L. Valentino, D. Cooper, B. Goldstein, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding

A. Go, K. Reynolds, Nigel Gupta, 2022, Journal of Thrombosis and Thrombolysis.

SHP656, a polysialylated recombinant factor VIII (PSA‐rFVIII): First‐in‐human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A

P. Collins, A. Tiede, M. Wolfsegger, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Recombinant single‐chain factor VIII in severe hemophilia: Long‐term safety and efficacy in previously treated patients in the AFFINITY extension study

J. Mahlangu, O. Stasyshyn, I. Pabinger, 2022, Research and practice in thrombosis and haemostasis.

Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.

R. Dolmetsch, J. Astermark, C. Hermans, 2023, The New England journal of medicine.

Interim Analysis of the Extension Study with rVIII-SingleChain in Previously Untreated Patients (PUPs) with Severe Hemophilia A (CSL627-3001)

E. Santagostino, K. Fischer, J. Mahlangu, 2019, Blood.

INR and vitamin K–dependent factor levels after vitamin K antagonist reversal with 4F-PCC or plasma

J. Goldstein, T. Milling, R. Sarode, 2022, Blood advances.